neoplasm metastasis/protease

This application is a National Phase application of PCT/EP2008/066879, filed Dec. 5, 2008, which claims benefit of EP 07122494.3, filed Dec. 6, 2007. FIELD OF THE INVENTION The present invention relates to the treatment or prevention of metastasis, or formation thereof, using a Protease nexin-1

BACKGROUND OF THE INVENTION Cysteine proteases, such as cathepsins B, L, S, and O.sub.2, have been implicated in a number of diseases, including cancer metastasis and invasion (Clin. Exp. Metastasis 1992, 10, 145-155; Cancer Metastasis Rev. 1990, 9, 333-352), arthritis (Int. J. Biochem. 1993, 25,

BACKGROUND OF THE INVENTION The invention relates generally to detecting diseases of the prostate, and more particularly, relates to reagents such as polynucleotide sequences and the polypeptide sequences encoded thereby, as well as methods which utilize these sequences, which are useful for

TECHNICAL FIELD OF THE INVENTION The invention relates to the area of regulation human transmembrane serine protease activity to provide therapeutic effects. BACKGROUND OF THE INVENTION Metastasizing cancer cells invade the extracellular matrix using plasma membrane protrusions that contact and

TECHNICAL FIELD OF THE INVENTION The invention relates to the area of regulation human transmembrane serine protease activity to provide therapeutic effects. BACKGROUND OF THE INVENTION Metastasizing cancer cells invade the extracellular matrix using plasma membrane protrusions that contact and

TECHNICAL FIELD OF THE INVENTION The invention relates to the area of regulation human transmembrane serine protease activity to provide therapeutic effects. BACKGROUND OF THE INVENTION Metastasizing cancer cells invade the extracellular matrix using plasma membrane protrusions that contact and

FIELD OF THE INVENTION THIS INVENTION relates to a metalloprotease that mediates proteolytic cleavage of proteins located at the cell surface. More particularly, this invention relates to ADAM 10 and/or ADAM17 metalloprotease-mediated proteolytic cleavage of substrate proteins, such as ligands for

BACKGROUND OF INVENTION Cysteine proteases, such as cathepsins B, H, K, L, S, and O.sub.2, containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as:

BACKGROUND OF THE INVENTION This invention pertains to a method of treatment for inhibiting the spread of malignant cells, or metastasis. "Metastasis", as used herein, is defined as the transfer of malignant tumor cells, or neoplasm, via preformed body vascular channels (blood vessels or

This application is a National Stage application of co-pending PCT application PCT/EP01/07116 filed Jun. 22, 2001, which was published in English under PCT Article 21(2) on Dec. 27, 2001, which claims the benefit of U.S. provisional application Ser. No. 60/213,474 filed Jun. 23, 2000 and Ser. No.

TECHNICAL FIELD OF THE INVENTION The invention relates to the area of enzyme regulation. More particularly, the invention relates to the regulation of human prostasin-like enzyme activity. BACKGROUND OF THE INVENTION Serine proteases are involved in a variety of biological functions, including

FIELD OF THE INVENTION This invention relates to inhibitors of cysteine proteases, especially those of the papain superfamily. The invention provides novel compounds useful in the prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin

FIELD OF THE INVENTION This invention relates to inhibitors of cysteine proteases, especially those of the papain superfamily. The invention provides novel compounds useful in the prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin

FIELD OF THE INVENTION This invention relates to inhibitors of cysteine proteases, especially those of the papain superfamily. The invention provides novel compounds useful in the prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin

FIELD OF THE INVENTION This invention relates to inhibitors of cysteine proteases, especially those of the papain superfamily. The invention provides novel compounds useful in the prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin